J 2011

Circulating Levels of Agouti-Related Peptide in Endometrial Cancer Survivors

BIENERTOVÁ VAŠKŮ, Julie, Josef TOMANDL, Petr BIENERT, Josef CHOVANEC, Zuzana DOSTÁLOVÁ et. al.

Basic information

Original name

Circulating Levels of Agouti-Related Peptide in Endometrial Cancer Survivors

Authors

BIENERTOVÁ VAŠKŮ, Julie (203 Czech Republic, guarantor, belonging to the institution), Josef TOMANDL (203 Czech Republic, belonging to the institution), Petr BIENERT (203 Czech Republic), Josef CHOVANEC (203 Czech Republic, belonging to the institution), Zuzana DOSTÁLOVÁ (203 Czech Republic), Anna VAŠKŮ (203 Czech Republic, belonging to the institution) and Dalibor VALÍK (203 Czech Republic, belonging to the institution)

Edition

World Journal of Oncology, 2011, 1920-4531

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30200 3.2 Clinical medicine

Country of publisher

Canada

Confidentiality degree

není předmětem státního či obchodního tajemství

RIV identification code

RIV/00216224:14110/11:00054212

Organization unit

Faculty of Medicine

DOI

Keywords in English

Agouti-related peptide; Cachexia; Cancer; Cancer survivors
Změněno: 6/6/2012 08:58, doc. RNDr. Josef Tomandl, Ph.D.

Abstract

V originále

Recently, it has been reported that central administration of agouti-related peptide (AgRP) might have protective effect against cachexia development in tumor-bearing mice. In this study, we determined whether the disease-free endometrial cancer survivors present with different plasma AgRP levels than controls and whether there was an association with the duration of the disease- free interval. The total of 53 endometrial cancer survivors was enrolled in the study along with 93 healthy control women of similar age. Fasting blood samples were obtained and AgRP plasma levels determined using ELISA-based methodology. The AgRP plasma levels were signifi cantly higher in the cases than in the controls; AgRP levels were the lowest in obese control women; on the contrary, the AgRP plasma levels were highest in non-obese cancer survivors. Moreover, we observed signifi cant differences in AgRP levels between the endometrial cancer survivors and the control subjects [p (for comparison of the cases and the controls) = 0.002]. In the regression modeling, AgRP was signifi cantly associated with the BMI as well as the case-control status, and the case-control differences in AgRP levels retained their statistical signifi cance also after adjustment for BMI. Disease-free endometrial cancer survivors who did not develop cachexia during their treatment as well as post-treatment period present with signifi cantly higher AgRP levels than the control population, independently on their BMI and menopausal status which could be indicative of the protective effect of circulating AgRP against cachexia development in endometrial cancer.